亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

西妥昔单抗 医学 皮疹 内科学 肿瘤科 临床研究阶段 头颈部癌 放射治疗 化疗 不利影响 外科 癌症 结直肠癌
作者
Jan Baptist Vermorken,José Manuel Trigo,Ricardo Hitt,P. Koralewski,Eduardo Díaz‐Rubio,Frédéric Rolland,Rainald Knecht,Nadia Amellal,Armin Schueler,Jose M Baselga
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:25 (16): 2171-2177 被引量:1059
标识
DOI:10.1200/jco.2006.06.7447
摘要

PURPOSE: To evaluate the efficacy and safety of the epidermal growth factor receptor-directed monoclonal antibody cetuximab administered as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) who experience disease progression on platinum therapy. PATIENTS AND METHODS: An open-label multicenter study in which patients with disease progression on two to six cycles of platinum therapy received single-agent cetuximab (initial dose 400 mg/m2 followed by subsequent weekly doses of 250 mg/m2) for > or = 6 weeks (single-agent phase). Patients who experienced disease progression could receive salvage therapy with cetuximab plus platinum (combination-therapy phase). From June 2001 to December 2002, 103 patients were enrolled and treated with cetuximab, 53 of whom subsequently received combination therapy. RESULTS: In the single-agent phase, response rate was 13%, disease control rate (complete response/partial response/stable disease) was 46%, and median time to progression (TTP) was 70 days. During the combination-therapy phase, the objective response rate was zero, disease control rate was 26%, and TTP was 50 days. Median overall survival was 178 days. Treatment was well tolerated. The most common cetuximab-related adverse events in the single-agent phase were skin reactions, particularly rash (49% of patients, mainly grade 1 or 2). There was one treatment-related death due to an infusion-related reaction. CONCLUSION: Single-agent cetuximab was active and generally well tolerated in the treatment of recurrent and/or metastatic SCCHN that progressed on platinum therapy. Response was comparable to that seen with cetuximab plus platinum combination regimens in the same setting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乐乐的应助被ZZWZHENG采纳,获得50
2秒前
自由完成签到,获得积分10
20秒前
parantal发布了新的文献求助10
24秒前
喜悦如萱完成签到,获得积分10
27秒前
英俊的傲珊完成签到,获得积分10
34秒前
35秒前
粗暴的莹发布了新的文献求助10
41秒前
44秒前
wangch198201发布了新的文献求助10
50秒前
焚天尘殇完成签到,获得积分10
50秒前
58秒前
ZZWZHENG发布了新的文献求助50
1分钟前
1分钟前
1分钟前
彩色听筠完成签到,获得积分10
1分钟前
林楠发布了新的文献求助10
1分钟前
Ttimer完成签到,获得积分10
1分钟前
干净书双完成签到,获得积分10
1分钟前
所所的应助被林楠采纳,获得10
1分钟前
1分钟前
打打的应助被adgn采纳,获得10
1分钟前
CodeCraft的应助被ryanchung采纳,获得30
1分钟前
1分钟前
1分钟前
高高的城发布了新的文献求助10
1分钟前
DD778完成签到,获得积分10
1分钟前
parantal发布了新的文献求助10
1分钟前
DD778发布了新的文献求助10
1分钟前
2分钟前
高高的城完成签到,获得积分10
2分钟前
ryanchung发布了新的文献求助30
2分钟前
2分钟前
老迟到的断秋完成签到,获得积分10
2分钟前
2分钟前
自觉的三娘完成签到,获得积分10
2分钟前
ZZWZHENG发布了新的文献求助60
2分钟前
奔跑的应助被欣喜寒烟采纳,获得10
2分钟前
2分钟前
whistle发布了新的文献求助10
2分钟前
宁静致远完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173069
求助须知:如何正确求助?哪些是违规求助? 9565519
关于积分的说明 21780407
捐赠科研通 7765088
什么是DOI,文献DOI怎么找? 3431532
关于科研通互助平台的介绍 2555638
邀请新用户注册赠送积分活动 2476668